- Sweden
- /
- Medical Equipment
- /
- OM:SEZI
Even after rising 13% this past week, Senzime (STO:SEZI) shareholders are still down 69% over the past five years
While it may not be enough for some shareholders, we think it is good to see the Senzime AB (publ) (STO:SEZI) share price up 30% in a single quarter. But that can't change the reality that over the longer term (five years), the returns have been really quite dismal. In that time the share price has delivered a rude shock to holders, who find themselves down 69% after a long stretch. So we're hesitant to put much weight behind the short term increase. Of course, this could be the start of a turnaround.
While the last five years has been tough for Senzime shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.
Given that Senzime didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
In the last half decade, Senzime saw its revenue increase by 46% per year. That's better than most loss-making companies. In contrast, the share price is has averaged a loss of 11% per year - that's quite disappointing. It's safe to say investor expectations are more grounded now. Given the revenue growth we'd consider the stock to be quite an interesting prospect if the company has a clear path to profitability.
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So we recommend checking out this free report showing consensus forecasts
A Different Perspective
While the broader market gained around 1.7% in the last year, Senzime shareholders lost 25%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 11% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should learn about the 4 warning signs we've spotted with Senzime (including 1 which doesn't sit too well with us) .
Senzime is not the only stock that insiders are buying. For those who like to find lesser know companies this free list of growing companies with recent insider purchasing, could be just the ticket.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Swedish exchanges.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:SEZI
Senzime
A medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States.
Adequate balance sheet with slight risk.
Market Insights
Weekly Picks

An Undervalued 3.3Moz Gold Project in Canada

GameStop will ace the financial crisis wave with its strategic Bitcoin investment and cash reserves
The First Real Lidar Winner

The Most Wonderful Monopoly in the Most Dangerous Neighbourhood on Earth
Recently Updated Narratives

A case for Steppe Gold, bear case CAD $4, base case CAD $15, bull case CAD $25
Lagenda Properties Berhad: Resilient Profitability and Deep Value in Malaysia’s Affordable Housing Sector
Huya joins hands with the original team of the Football Super League to kick off the 2026 Jiangsu E-Sports Super League
Popular Narratives

Everyone's Terrified Microsoft Will Keep Spending. I'm Terrified They'll Stop.

The academically fascinating Tesla
